Treatment options in hormone resistant prostate cancer
Open Access
- 1 October 2002
- journal article
- review article
- Published by Elsevier in Annals of Oncology
- Vol. 13, 95-102
- https://doi.org/10.1093/annonc/mdf645
Abstract
Department of 1Medical Oncology and 2Urology, University Medical Center Nijmegen, Nijmegen, The Netherlands; 3Foundation Vincenzo Pansodoro, Rome, ItalyKeywords
This publication has 46 references indexed in Scilit:
- Expression of basal cell keratins in human prostate cancer metastases and cell linesThe Journal of Pathology, 2001
- Molecular Biology for UrologistsEuropean Urology, 2001
- ANDROGEN RECEPTOR GENE AMPLIFICATION AT PRIMARY PROGRESSION PREDICTS RESPONSE TO COMBINED ANDROGEN BLOCKADE AS SECOND LINE THERAPY FOR ADVANCED PROSTATE CANCERJournal of Urology, 2000
- Declining Rates of Extracapsular Extension After Radical Prostatectomy: Evidence for Continued Stage MigrationJournal of Clinical Oncology, 1999
- Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer.Journal of Clinical Oncology, 1993
- High-dose continuous-infusion fosfestrol in hormone-resistant prostate cancerCancer, 1993
- Flutamide in Hormone-Resistant Prostatic CancerJournal of Urology, 1990
- Effect of High-dose Medroxyprogesterone Acetate on Plasma Hormone Levels and Pain Relief in Patients with Advanced Prostatic CancerBritish Journal of Urology, 1990
- Adrenal androgen blockade in relapsed prostate cancerEuropean Journal of Cancer and Clinical Oncology, 1985
- KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCERThe Lancet, 1984